Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Sep 4, 2023
Date Accepted: Mar 4, 2024

The final, peer-reviewed published version of this preprint can be found here:

Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy

Aye PS, Barnes J, Laking G, Cameron L, Anderson M, Luey B, Delany S, Harris D, McLaren B, Brenman E, Wong J, Lawrenson R, Arendse M, Tin Tin S, Elwood M, Hope P, McKeage MJ

Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy

JMIR Res Protoc 2024;13:e51381

DOI: 10.2196/51381

PMID: 38954434

PMCID: 11252616

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Per the author's request this version is not available.